Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmProCure: CC-1 and VAC-XS15-PC01 in Biochemical Relapse of Prostate Cancer
NCT07860047Phase 2Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Multi-peptide vaccine VAC-XS15-PC01, PSMAxCD3 bispecific antibody CC-1 and CC-1 + VAC-XS15-PC01 (3 arms). Primary endpoint: Prostate Specific Antigen response. Started Sep 2026; status: recruiting.
02
Drugs
CC-1VAC-XS15-PC01
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07860047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860047.